Dosing Regarding Venetoclax

Dosing Regarding Venetoclax

moasc

10 months
145 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Deepa Jeyakumar, M.D. Assistant Clinical Professor, Division of Hematology/Oncology At University of California Irvine Discusses Dosing Regarding Venetoclax. At MOASC on Jan 19, 2019.
Up Next Autoplay
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 1 day
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
Category: Acute Myelogenous Leukemia
15 Views
Cancer-News 1 month
How to Manage MDS Patients who are Ineligible for Transplant
How to Manage MDS Patients who are Ineligible for Transplant
Category: Acute Myelogenous Leukemia
300 Views
obr 5 months
The Recent Wave of Approval in AML
The Recent Wave of Approval in AML
Category: Acute Myelogenous Leukemia
138 Views
obr 5 months
Updated Data on Gilteritinib in AML
Updated Data on Gilteritinib in AML
Category: Acute Myelogenous Leukemia
16 Views
obr 5 months
Latest Data on Uproleselan with Chemotherapy
Latest Data on Uproleselan with Chemotherapy
Category: Acute Myelogenous Leukemia
100 Views
obr 5 months
AML Case: A 54-year-old woman is in remission but MRD+
AML Case: A 54-year-old woman is in remission but MRD+
Category: Acute Myelogenous Leukemia
115 Views
imedex 6 months
Update: New Drugs for AML
Update: New Drugs for AML
Category: Acute Myelogenous Leukemia
177 Views
imedex 6 months
Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing
Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And Azacitidine Have Proven As Effective As Standard Dosing
Category: Acute Myelogenous Leukemia
100 Views
Annual-Meeting 6 months
Should We Check If The Donor Has A Mutation: Depends On The Type Of Mutation, Not Every Mutation Is The Same
Should We Check If The Donor Has A Mutation: Depends On The Type Of Mutation, Not Every Mutation Is The Same
Category: Acute Myelogenous Leukemia
107 Views
Annual-Meeting 6 months